Showing results (221-230 of 265) with videos related to

Sort By:
Pageof 27
The Pharmacogenomics Journal|March 30, 2016
Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemiaH Alachkar, N Fulton, B Sanford, et al.
Arthritis and Rheumatism|March 1, 2007
No evidence for genetic association of interferon regulatory factor 1 in juvenile idiopathic arthritisMark S Fife, Laura Gathercole, Emma M Ogilvie, et al.
Medical Care|October 17, 2013
Thirty years of disparities intervention research: what are we doing to close racial and ethnic gaps in health care?Amanda R Clarke, Anna P Goddu, Robert S Nocon, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 17, 2002
Genomic structure and functional control of the Dlx3-7 bigene clusterKenta Sumiyama, Steven Q Irvine, David W Stock, et al.
International Journal of Colorectal Disease|June 7, 2002
Neurogenic appendicopathy: a clinical disease entity?C Franke, C D Gerharz, H Böhner, et al.
Experimental Hematology|July 2, 1999
Defective expression of the SHP-1 phosphatase in polycythemia veraA Wickrema, F Chen, F Namin, et al.
Bone Marrow Transplantation|November 1, 1995
A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapyJ A Sosman, P J Stiff, R A Bayer, et al.
Arthritis Research & Therapy|September 9, 2006
Novel IL10 gene family associations with systemic juvenile idiopathic arthritisMark S Fife, Ana Gutierrez, Emma M Ogilvie, et al.
The Journal of Clinical Investigation|July 6, 2000
Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapyT A Fehniger, E M Bluman, M M Porter, et al.
Bone Marrow Transplantation|January 10, 2006
Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioningJ Kline, D A Pollyea, W Stock, et al.
Pageof 27